AzTrials
AzTrials

Platelet-Rich PlasmaPhase 4NCT03779945

Effect of Platelet-Rich-Plasma in Spine Fusion

A Phase 4 study testing autologous platelet rich plasma and posteriolateral lumbar fusion only in people with Platelet-Rich Plasma, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The objective of this study is to evaluate the fusion rate after the use of platelet rich plasma with autolgus bone graft and comparing it with bone graft alone Read more about this study

Who is it for?
Ages 20 to 75 years
Conditions the study is for
Platelet-Rich Plasma
What is being tested?
autologous platelet rich plasma and posteriolateral lumbar fusion only
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
No sites listed yet
Study dates
20 Dec 2018to 20 Jan 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • degenerative or lytic Spondylolisthesis.
  • Degenerative disc disease requiring posterior lumbar fusion not responding to medical treatment for 1 year.
  • Age between 20 \& 75 years.
  • Single level fusion

Who cannot join

  • Multiple levels patient Traumatic Spondylolisthesis Previous lumbar spine surgery. Other lumbar spine pathology severe osteoporosis Patients younger than 20 years old. Patients older than 75 years old. Immunocompromised patients (eg. Chronic renal failure)

Trial locations and contacts

No sites are listed yet.

Micheal B Elia, doctor contact

01282682989 ext. +2

mikelbassem@hotmail.com

About this study

Official title: Application of Platelet-Rich-Plasma in Posterolateral Lumbar Fusion

The objective of this study is to evaluate the fusion rate after the use of platelet rich plasma with autolgus bone graft and comparing it with bone graft alone

Read the detailed description

The study will be submitted for approval by the Ethics Committee of Faculty of Medicine, Assiut University, and written informed consent will be obtained from all patients prior to enrollment. The study population will be selected from patients attending the Department of Orthopedics and Trauma surgery, Assiut University hospitals.

A total of 104 patients treated with single level degenerative or lytic lumbar Spondylolisthesis indicated for PLF will be included ,patients will be classified into 2 groups Group A:Of 52 patients PLF + autologus bone graft+ PRP Group B: Of 52 patients treated with PLF + autologus bone graft only without adding PRP

Methods of evaluation

  • History taking.
  • Full clinical and neurological examination
  • Radiological evaluation by x-ray (antero posterior, lateral, and, CT scans provide excellent views of bony detail) and MRI if needed Method of randomization By shuffling cards method the candidate patient will choose one card from104 cards 52 of them containing fusion with PRP and the other 52 contaning Fusion without PRP

Platelet-rich plasma (PRP is obtained using a two-stage centrifugation process:

Whole blood sample will be drawn from the participant and be collected in a sterile tube containing anticoagulant (sodium citrate 3.8% or Ethylenediaminetetra acetic acid). The tube will be centrifuged at 160xg relative centrifugal force (about 1000 round per minute) for 10 min in a centrifugal apparatus. The first spin will separate platelet poor plasma at the top from red blood cells at the bottom and platelet rich plasma above (mixed with the white blood cells in the buffy coat). The Platelet poor plasma, Platelet rich plasma and a few red blood cells will be aspirated into a new tube, mixed and in the second spin, the tube will be centrifuged at 400xg relative centrifugal form (about 1500 round per minute) for another 10 minutes. The upper section will consist of Platelet poor plasma and the Platelet rich plasma will be collected at the bottom of the tube in the form of pellet. Then, Platelet poor plasma and Platelet rich plasma will be aspirated and mixed (discarding the upper portion). Prior to treatment calcium chloride 3% will be added to activate platelets specimen

Being tested
autologous platelet rich plasma, posteriolateral lumbar fusion only
Keywords
PRP

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • autologous platelet rich plasmaBiological

    adding autologous platelet rich plasma to the bone graft harvested from the patient

  • posteriolateral lumbar fusion onlyProcedure or surgery

    performing posteriolateral lumbar fusion without using platelet rich plasma

Study groups in NCT03779945
Study groupRoleWhat they receive
posteriolateral lumbar fusion +bone graft+ PRPActive comparatorthe addition of autologous platelet rich plasma to the bone graft
Receives: Biological: autologous platelet rich plasma
posteriolateral lumbar fusion+bone graft onlyActive comparatorposteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
Receives: Procedure: posteriolateral lumbar fusion only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Lenke classification of posterolateral fusion success

    the degree of bridging bone across the fused vertebral bodies by using xray and CT scan

    Measured: 6 month to1 year post-operative

Secondary outcomes (2)
  1. modified Oswestry disability index ,

    the functional outcome on the patient

    Measured: 6 month to 1 year post-operative

  2. visual analogue scale

    the amount of pain sensed by the patient pre and post-operative

    Measured: 6 month to 1 year post-operative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2018
  2. Study start20 Dec 2018 (estimated)
  3. Primary completion20 Dec 2019 (estimated)
  4. Study completion20 Jan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
single center, prospective randomized comparative trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03779945
Sponsor's protocol ID
PRP in lumbar fusion
Status last verified
Dec 2018
First submitted
17 May 2018
Last updated
20 Dec 2018
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kubota G, Kamoda H, Orita S, Yamauchi K, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Sato J, Ito M, Yamashita M, Nakamura J, Suzuki T, Takahashi K, Ohtori S. Platelet-rich plasma enhances bone union in posterolateral lumbar fusion: A prospective randomized controlled trial. Spine J. 2019 Feb;19(2):e34-e40. doi: 10.1016/j.spinee.2017.07.167. Epub 2017 Jul 20.

    PubMed 28735763
  • Shiga Y, Orita S, Kubota G, Kamoda H, Yamashita M, Matsuura Y, Yamauchi K, Eguchi Y, Suzuki M, Inage K, Sainoh T, Sato J, Fujimoto K, Abe K, Kanamoto H, Inoue M, Kinoshita H, Aoki Y, Toyone T, Furuya T, Koda M, Takahashi K, Ohtori S. Freeze-Dried Platelet-Rich Plasma Accelerates Bone Union with Adequate Rigidity in Posterolateral Lumbar Fusion Surgery Model in Rats. Sci Rep. 2016 Nov 11;6:36715. doi: 10.1038/srep36715.

    PubMed 27833116
  • Imagama S, Ando K, Kobayashi K, Ishikawa Y, Nakamura H, Hida T, Ito K, Tsushima M, Matsumoto A, Morozumi M, Tanaka S, Machino M, Ota K, Nakashima H, Takamatsu J, Matsushita T, Nishida Y, Ishiguro N, Matsuyama Y. Efficacy of Early Fusion With Local Bone Graft and Platelet-Rich Plasma in Lumbar Spinal Fusion Surgery Followed Over 10 Years. Global Spine J. 2017 Dec;7(8):749-755. doi: 10.1177/2192568217696690. Epub 2017 Apr 11.

    PubMed 29238638
  • Tarantino R, Donnarumma P, Mancarella C, Rullo M, Ferrazza G, Barrella G, Martini S, Delfini R. Posterolateral arthrodesis in lumbar spine surgery using autologous platelet-rich plasma and cancellous bone substitute: an osteoinductive and osteoconductive effect. Global Spine J. 2014 Aug;4(3):137-42. doi: 10.1055/s-0034-1376157. Epub 2014 May 3.

    PubMed 25083353

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing autologous platelet rich plasma and posteriolateral lumbar fusion only in people with Platelet-Rich Plasma, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Micheal B Elia, doctor (01282682989 ext. +2, mikelbassem@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Lenke classification of posterolateral fusion success (time frame: 6 month to1 year post-operative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03779945, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in